Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial.

Poddubnyy, Denis; Pournara, Effie; Zielinska, Agnieszka; Baranauskaite, Asta; Jiménez, Alejandro Muñoz; Sadhu, Sanchayita; Schulz, Barbara; Rissler, Michael; Perella, Chiara; Marzo-Ortega, Helena

Poddubnyy, Denis; Pournara, Effie; Zielinska, Agnieszka; Baranauskaite, Asta; Jiménez, Alejandro Muñoz; Sadhu, Sanchayita; Schulz, Barbara; Rissler, Michael; Perella, Chiara; Marzo-Ortega, Helena.

Afiliação

Poddubnyy D; Head of the Rheumatology Unit, Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany.
Pournara E; Novartis AG, Basel, Switzerland.
Zielinska A; Medycyna Kliniczna, Warszawa, Poland.
Baranauskaite A; Lithuanian University of Health Sciences, Kaunas, Lithuania.
Jiménez AM; Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Sadhu S; Novartis Healthcare Private Limited, Hyderabad, India.
Schulz B; Novartis AG, Basel, Switzerland.
Rissler M; Novartis AG, Basel, Switzerland.
Perella C; Novartis AG, Basel, Switzerland.
Marzo-Ortega H; NIHR Leeds Biomedical Research Centre, LTHT and LIRMM, University of Leeds, Leeds, UK.

Ther Adv Musculoskelet Dis ; 13: 1759720X211051471, 2021.

Article em En | MEDLINE | ID: mdl-34707696

Palavras-chave

axial spondyloarthritis; interleukin-17A inhibitor; spinal pain; tumour necrosis factor inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Ther Adv Musculoskelet Dis Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google